Fund Evaluator:
Global X Genomics & Biotechnology ETF (GNOM)
Follow This Fund
Equity
Global Asset Class
Sector Equity
Fund Group
Health
Category
$12.490
NAV (as of Oct 07)
$0.00
Minimum Initial
0.50% C
Expense Ratio
$91 Mil
Assets
Open
Status
na
12b-1 Fee
1.01%
TTM Yield
0.00%
Max Load
34%
Portfolio Turnover
Best Performing in Health Over the Last Year
| 67.1% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 66.9% | Fidelity Advisor Biotechnology I (FBTIX) |
| 58.0% | Fidelity Select Biotechnology (FBIOX) |
| 54.2% | Rydex Biotechnology Inv (RYOIX) |
| 49.7% | Eventide Healthcare & Life Sciences N (ETNHX) |
Data as of 8/31/2026
18.6% A
1-Mo Return
30.2% A
3-Mo Return
41.8% A
YTD Return
78.1% A
1-Yr Return
13.4% C
3-Yr Return
-7.4% F
5-Yr Return
1.54 F
Category Risk Index
2.57
Total Risk Index
Fund Details
Fund Family
Global X Funds
Inception Date
4/5/2019
Share Class Type
Equity Investment Style
Small-Cap
Blend
Bond Investment Style
na
Socially Responsible Fund
No
Index Fund
Yes
Benchmark Index
MSCI ACWI NR USD: 100%
Additional Fund Details
Global X Genomics & Biotechnology ETF Overview
GNOM Trailing NAV Total Returns Data as of 8/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| GNOM Return (NAV) | 18.6% | 30.2% | 78.1% | 13.4% | -7.4% | na |
| GNOM Grade | A | A | A | C | F | na |
| +/- Category | 13.6% | 16.7% | 45.2% | 0.3% | -12.7% | na |
| Health Avg | 5.0% | 13.4% | 32.9% | 13.1% | 5.2% | 10.2% |
| GNOM Tax Cost Ratio | na | na | 0.6% | 0.2% | 0.1% | na |
GNOM Annual NAV Total ReturnsData as of 8/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| GNOM Return (NAV) | 41.8% | 19.0% | -16.2% | -8.6% | -36.1% | -16.0% | 51.6% | na | na | na | na |
| GNOM Grade | A | C | F | F | F | F | A | na | na | na | na |
| +/- Category | 29.3% | -1.6% | -18.7% | -14.2% | -26.7% | -24.7% | 27.2% | na | na | na | na |
| Health Avg | 12.5% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | 31.3% |
| Total Risk Index: | 2.57 - High |
| Category Risk Index: | 1.54 - High |
| Category Risk Grade: | F (98% Rank) |
| Beta: | 1.63 |
| R-Squared: | 42% |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Small-Cap Blend |
| Bond Investment Style: | na |
| Yield: | 1.0% |
| Dividend Distribution: | Semi-Annually |
| Cap Gains Distribution: | |
| Total Assets: | $91 Mil |
| Fund Total Assets: | $ 92 Mil |
| Share Class Type: | |
| Portfolio Turnover: | 34% |
Management Team
| Number of Managers: 2 | |||
| Longest Tenure: 7.4 years | |||
| Average Tenure: 7.4 years | |||
| Managers (Year): To Nam (2019), Xie Wayne (2019) | |||
Portfolio Composition (as of 8/31/26)
| # of Holdings: | 51 |
| % in Top 10 Holdings: | 48.8% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 6.3% |
Portfolio Allocation |
|
| Domestic Stock: | 93.7% |
| Foreign Stock: | 6.3% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.0% |
Purchase Information
| Fund Family: | Global X Funds |
| Phone Number: | 888-493-8631 |
| Website: | www.globalxfunds.com |
| Status: | Open |
| Inception Date: | April 5, 2019 |
| Min. Initial Purchase: | $ 0 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | na |
Expenses and Fees | |
| Expense Ratio (%): | 0.50% ( Rating : Avg ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | Global X Genomics & Biotechnology ETF |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
Copyright 2026 American Association of Individual Investors and Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.